|
 |
|
|
|
 |
|
|
|
 |
|
|
 |
|
 |
|
|
|
|
|
 |
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4-Panel CLIA Waived EZ Integrated Drug Testing Cup
|
|
|
|
|
|
|
|
|
|
Fully Integrated Design eliminates handling of the urine.
Only the collector can activate the test, thus eliminating
donor manipulation. Label hides test result from those
who do not need to view results. The test is a fast
visual, competitive panel immunoassay that can be used
for the simultaneous, qualitative detection of a specific
drug metabolite in human urine. The EZ-Cup is a CLIA
Waved Device, FDA 510(K) cleared to market and uses
SAMHSA approved guidelines. It is ideal for
pre-employment, random, reasonable cause,
corrections, clinical, hospital, and personal use.
|
|
|
|
 |
|
|
|
|
|
Features & Benefits
- FDA 510(K) Cleared
- CLIA Waved
- The cup has easy Xerox feature where
cup can be laid down on its side; doesn’t
leak
- Up to 99% Accurate
- Adheres to the SAMHSA Cutoffs
- Immediate Results
- Shelf-life of 18-24 months
- The new key feature. No more turning,
simply put the key in and push.
- New easy to open top for the
confirmation lab
- The collector retains control of the
chemistry & can time the results to
insure proper interpretation.
|
|
|
|
Tests for 4 Drugs
|
|
|
|
|
|
Marijuana (THC) 50 ng/ml
Cocaine (COC) 300 ng/ml
Methamphetamine (METH) 1000 ng/ml
Morphine/Opiates (MOR) 2000 ng/ml.
|
|
|
|
|
Want to know how long a specific
drug is detectable in urine? Check
out our detection timetable page.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
QTY
|
1 - 9
|
10 - 24
|
25 - 49
|
50 - 99
|
100-299
|
300 +
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
Privacy Guarantee your
personal information is
safe with us.
Safe, Secure Shopping -
128-Bit SSL security for
safest shopping.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
